Xiaochu Li³

Xiaochu Li³


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YCYangting Cai
Yangting Cai
RHRuize Huang
Ruize Huang
XZXianjin Zhang
Xianjin Zhang
QWQing Wang
Qing Wang
CCCaiyuan Chen
Caiyuan Chen
QLQiang Lin
Qiang Lin
Summary This study provides a comprehensive bibliometric analysis and narrative synthesis of research on osteosarcopenia over the past decade, highlighting evolving research trends, key contributors, and emerging clinical priorities. Introduction Osteosarcopenia, characterized by the coexistence of osteoporosis and sarcopenia, is increasingly recognized as a clinically significant geriatric syndrome associated with adverse health outcomes. However, global research trends and emerging hotspots in this field have not yet been comprehensively characterized. Methods A bibliometric analysis was conducted using data retrieved from the Web of Science Core Collection. Bibliometrix, VOSviewer, SCImago Graphica, and OriginPro were used to analyze publication trends, authorship patterns, institutional contributions, and keyword co-occurrence networks. In addition, a narrative review was conducted to synthesize current evidence on the epidemiology, pathophysiology, diagnosis, and management of osteosarcopenia. Results A total of 245 publications were included, demonstrating a steady increase in annual publication output and citation impact. China, Japan, and Australia were among the leading contributing countries, and collaboration networks were concentrated around prominent institutions. Keyword co-occurrence analysis identified major research clusters encompassing risk factors, diagnostic assessment, therapeutic strategies, and prognosis. The narrative synthesis further indicated that osteosarcopenia is associated with an increased risk of falls, fractures, mortality, and functional decline. Despite advances in imaging and assessment techniques, diagnostic criteria remain inconsistent, and current therapeutic approaches are largely extrapolated from those used to manage osteoporosis. Conclusion Research on osteosarcopenia has expanded substantially over the past decade, reflecting growing recognition of its clinical significance. Nevertheless, important knowledge gaps remain, particularly regarding standardized diagnostic criteria and targeted therapeutic strategies. Future research should prioritize longitudinal studies, mechanistic investigations, and multidisciplinary management approaches to improve clinical outcomes in aging populations.

7 February 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YCYanting Chen
Yanting Chen
LLLeying Lin
Leying Lin
JLJinlong Li
Jinlong Li
WSWeishan Sun
Weishan Sun
XLXiaochu Li³
Xiaochu Li³
QWQingrong Wu
Qingrong Wu
The efficacy of Chinese herbal medicine (CHM) in treating dyslipidaemia has been demonstrated. However, the prevalence of CHM treatment and factors influencing its use in middle-aged and older patients with dyslipidaemia in China remain unclear. We aimed to investigate the prevalence and contributing factors of CHM use among middle-aged and older Chinese patients with dyslipidaemia. The data analyzed in this study were extracted from the fourth wave (2018) of the China Health and Retirement Longitudinal Study (CHARLS). Information on demographic and socioeconomic characteristics, health service use, health status, and history of CHM use was obtained. A logistic regression model was used to identify the key factors (demographics, health service use, and health status) that predict CHM use in the treatment of dyslipidaemia. In this cross-sectional study, a total of 4341 participants (middle-aged adults, 56.46%; older adults, 42.36%; males, 45.06%; females, 54.94%) with dyslipidaemia were included, and the prevalence of CHM use for dyslipidaemia was 14.08%. A logistic regression analysis revealed that compared with participants who did not use CHM, those who used CHM were more likely to have no income (OR 1.33; 95% CI 1.02, 1.74), visit traditional Chinese medicine hospitals (OR 2.85; 95% CI 1.71, 4.74), engage in self-treatment (OR 1.70; 95% CI 1.35, 2.13), report fair or poor health status (fair, OR 1.60; 95% CI 1.13, 2.26; poor, OR 1.99; 95% CI 1.36, 2.86), and a higher modified Chinese multimorbidity-weighted index (OR 1.06; 95% CI 1.03, 1.10). In the joint effect analysis, patients who visited a Chinese medicine hospital and had a stroke were more likely to use CHM (OR 6.90; 95% CI 2.08, 22.88) than those who did not visit a Chinese medicine hospital and did not have a stroke. In this study, the prevalence of CHM use was 14.08% among middle-aged and older patients with dyslipidaemia and was correlated with demographic factors, multimorbidity, and health service preferences in China. These findings suggest the need to integrate patient-specific factors into CHM-based dyslipidaemia management strategies.